Evidence method
Sequential · gp.financial.deposits
-0.76% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
GDOT · Dec 31, 2022
GREEN DOT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001386278-23-000007Bank
Evidence method
Yoy · gp.fundamentals.net_income
35.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.cash
$813.9M · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Jun 30, 20213/3 normalizedLevel 3Dec 31, 20213/3 normalizedLevel 3Mar 31, 20223/3 normalizedLevel 3Jun 30, 20223/3 normalizedLevel 3Sep 30, 20224/4 normalizedLevel 3Dec 31, 20223/3 normalizedLevel 3Mar 31, 20234/4 normalizedLevel 3Jun 30, 20234/4 normalizedLevel 3Sep 30, 20234/4 normalizedLevel 3Dec 31, 20234/4 normalizedLevel 3Mar 31, 20244/4 normalizedLevel 3Jun 30, 20244/4 normalizedLevel 3Sep 30, 20243/3 normalizedLevel 3Dec 31, 20244/4 normalizedLevel 3Mar 31, 20254/4 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20264/4 normalizedLevel 3Jun 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 2.98%
- Current
- -0.76%
- Delta
- -3.74%
- Previous
- -35.98%
- Current
- 35.24%
- Delta
- 71.22%
- Previous
- $813.2M
- Current
- $813.9M
- Delta
- $735,000
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.